Fekra Therapeutics is developing new therapeutics to treat cancer. Using their small molecule platform, Curiositome, Fekra is exploring the cell to find cure to patients with devastating diseases. Fekra’s lead program, FT-01, targets the cytoplasmic tyrosine kinase, BMX, for castration-resistant prostate cancer. To design their BMX inhibitor, Fekra used structure-based design and are building a pipeline of projects to also find therapies for solid tumors and non-solid tumors.

Fekra Therapeutics

Founded: 2020
Location: Boston, MA
Employee range: 1 - 10
Clinical stage: Castration-resistant prostate cancer
Therapy area: FT-02 RD solid tumors; FT-03 RD non-solid tumors; FT-04 RD inflammatory
Drug types: ONC, IMM
Lead product: FT-01

About:

Jobs: